Evolent Health reports developments tied to its healthcare services business for people with complex conditions. Company news commonly covers operating and financial results, customer activity with health plans and providers, and the Performance Suite contract model used in its specialty care operations.
Recurring updates also include Evolent's complex specialty care focus in oncology, cardiology and musculoskeletal conditions, management participation in healthcare investor conferences, leadership appointments, board and compensation matters, and equity-award disclosures under NYSE rules.
On October 6, 2021, WindRose Health Investors announced the sale of Vital Decisions, a provider of technology-enabled advance care-planning services, to Evolent Health (NYSE: EVH). This acquisition positions Vital Decisions under Evolent's specialty management division, New Century Health, thus integrating into Evolent’s Clinical Solutions segment. Vital Decisions aims to ensure individuals' healthcare aligns with their values using advanced methodologies and analytics. WindRose had partnered with Vital Decisions since 2012, resulting in significant growth.
Evolent Health, Inc. (NYSE: EVH) announced participation in upcoming investor conferences by CEO Seth Blackley and CFO John Johnson. They will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 3:30 p.m. ET, with a live webcast available on Evolent's website. Additionally, they will present at the 2021 Cantor Global Healthcare Conference on September 27, 2021, at 9:20 a.m. ET. Evolent is known for delivering clinical and administrative solutions that improve health care efficiency and affordability.
Evolent Health, Inc. (NYSE: EVH) announced its acquisition of Vital Decisions from WindRose Health Investors for $85 million, with potential earn-outs up to $45 million. This strategic acquisition aims to integrate Vital Decisions' technology-enabled advance care planning services into Evolent's Clinical Solutions segment, enhancing patient engagement and care alignment. The deal is expected to provide significant clinical and financial synergies while being accretive to EBITDA per share. The transaction is projected to close later this year, pending regulatory approvals.
Evolent Health, Inc. (NYSE: EVH) reported financial results for Q2 2021, achieving GAAP revenue of $222.1 million, a 2.2% increase year-over-year. Organic revenue growth was notably high at 42.3%. However, the company recorded a net loss of $(9.1) million. Adjusted EBITDA rose to $13.3 million, up $2.8 million from Q2 2020. Evolent announced key acquisitions and partnerships that reflect a strategic push for growth, including the acquisition of Vital Decisions. The company also raised its full-year revenue guidance to $870-$900 million.
Evolent Health (NYSE: EVH) will have CEO Seth Blackley and CFO John Johnson present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 12:00 p.m. ET. A live webcast of the event will be available on Evolent's investor relations website. Evolent Health specializes in delivering clinical and administrative solutions to enhance healthcare affordability and manage total costs. The company has received the Population Health Program Accreditation and is recognized as a leader in healthcare service delivery.
Evolent Health (NYSE: EVH) will announce its second quarter 2021 operating results on August 4, 2021, after the market closes. A conference call will take place at 6:00 p.m. Eastern Time the same day, allowing shareholders to participate via phone. Evolent Health specializes in clinical and administrative healthcare solutions aimed at improving total care management. The company has achieved notable accreditations and is recognized for its workplace culture.
Summary not available.
Evolent Health (NYSE: EVH) has announced that CEO Seth Blackley and CFO John Johnson will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The event will feature a live webcast available on Evolent's investor relations website. Evolent Health provides clinical and administrative solutions aimed at improving health care affordability and simplicity for payers and providers, serving a national client base and recognized for its quality and workplace culture.
Evolent Health, Inc. (EVH) reported Q1 2021 GAAP revenue of $215.1 million, down from $221.2 million in Q1 2020. The net loss attributable to shareholders improved significantly to $(9.8 million), compared to $(78.8 million) in the prior year. Adjusted EBITDA was $14.9 million, a notable increase from $3.9 million in Q1 2020. With approximately 11.6 million lives managed, the company announced new partnerships aimed at expanding services in oncology and cardiology. CEO Seth Blackley emphasized strong demand for their solutions and targeted mid-teens organic growth.
Evolent Health, Inc. (EVH) reported a GAAP revenue of $215.1 million for Q1 2021, marking a decrease from $221.2 million in Q1 2020. The company achieved an Adjusted EBITDA of $14.9 million, up from $3.9 million year-on-year. A net loss attributable to shareholders was $(9.8) million, an improvement from $(78.8) million in 2020. Evolent is managing approximately 11.6 million lives and has announced new partnerships to enhance its service offerings. CEO Seth Blackley expressed optimism about the company's trajectory towards organic growth and margin expansion.